News

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the…
Read More...

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the…
Read More...

"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent demonstrate our commitment…
Read More...

Results from the INMARK study, a randomised, double-blind clinical trial of Ofev (nintedanib) vs. placebo (12 weeks) followed by an open label period (40 weeks) in patients with…
Read More...

Astellas Pharma Inc. and Frequency Therapeutics, Inc. announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative…
Read More...

TraceLink Inc. announced a partnership with Excellis Health Solutions to provide local implementation services for TraceLink's Russia compliance solution, helping pharmaceutical…
Read More...

Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of…
Read More...

Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), are…
Read More...

Quotient Sciences and global investment firm Permira announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from…
Read More...

The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract…
Read More...

Lonza has selected Rockwell Automation for the turnkey implementation of the Lonza strategic vision of bringing the digital factory to nine former Capsugel facilities that manufacture…
Read More...

Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht…
Read More...

Novartis announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle…
Read More...

AM-Pharma B.V., a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline…
Read More...

Kite, a Gilead Company (Nasdaq: GILD), announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a…
Read More...

Sosei Group Corporation announces that it has entered into a multi-target research collaboration and license agreement with Genentech, a member of the Roche Group, to discover and…
Read More...

Dicerna Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to DCR-PHXC for the treatment of patients…
Read More...

AbbVie, a research-based global biopharmaceutical company, announced that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel…
Read More...

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing…
Read More...